Head and neck cancer is the sixth most common cancer globally, yet its standard of care hasn't changed in a century. Our CEO, Harald Steltzer, recently joined the Diagnosing DX podcast to discuss how OrisDX is bringing precision medicine to the dental chair.
For 100 years, detecting head and neck cancer has solely relied on a visual inspection of the oral cavity. Unfortunately, by the time a lesion looks suspicious to the naked eye, it’s often late-stage, leading to invasive, disfiguring surgeries.
OrisDX is moving detection from sight to science. Our salivary rinse test uses Next-Generation Sequencing (NGS) to identify cancer-causing mutations in DNA shed directly from oral tumors.
The Oro Lesion testing process is:
Dentists and hygienists are the primary front line for oral health. OrisDX is bridging the gap between dental and medical care by providing a clear diagnostic path. To ensure no patient gets lost in the system, Oris Bridge, our Patient Health Navigator, will help those with positive results navigate referrals, insurance, and specialist care.
As we look toward our launch in 2026, our mission remains clear: removing the friction from diagnostics to save lives through early, accurate detection.
🎧 Listen now on:
🔹 YouTube: https://www.youtube.com/watch?v=L_pkEKg8c_Q
📺 Watch now on YouTube: